Showing results 1 to 7 of 7
| Title | Author(s) | Issue Date | Views | |
|---|---|---|---|---|
A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population Proceeding/Conference:Journal of Hepatology | 2017 | 45 | ||
| 2019 | 11 | |||
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV Proceeding/Conference:Hepatology | 2018 | 18 | ||
| 2018 | 69 | |||
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBVactivity in chronic hepatitis B patients and is safe and well tolerated Proceeding/Conference:Journal of Hepatology | 2018 | 42 | ||
RO7049389, a core protein allosteric modulator, is safe and well tolerated in healthy volunteers and demonstrates potent anti-HBV activity in a phase 1 trial Proceeding/Conference:Journal of Viral Hepatitis | 2018 | 54 | ||
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology | 2019 | 24 |